1-[2-(2-chloro-ethoxy)-ethoxy]-propane | 6913-71-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2-(2-chloro-ethoxy)-ethoxy]-propane
• 英文别名: 1-[2-(2-Chloroethoxy)ethoxy]propane
• CAS: 6913-71-9
• 化学式: C₇H₁₅ClO₂
• 分子量: 166.648
• InChiKey: VXVCVSVHGCRHOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[2-(2-乙基己氧基)乙氧基]乙醇 、 1-[2-(2-chloro-ethoxy)-ethoxy]-propane 在 phase transfer catalyst 作用下， 生成 1-[2-[2-[2-(2-Propoxyethoxy)ethoxy]ethoxy]ethoxy]octane
  参考文献：
  名称：

  通过拉曼光谱研究固态三嵌段低聚物 α-辛基-ω-n-烷氧基四（氧乙烯）的链长依赖性构象行为

  摘要：

  摘要 三嵌段低聚物 α-辛基-ω-n-烷氧基四(氧乙烯)s, H(CH2)8(OCH2CH2)4O(CH2)nH（n = 2-7）的拉曼光谱是在固态下测量的，并且检查了改变烷基链长度的构象行为。这些化合物的分子构象是通过基于法向坐标计算的光谱分析确定的。随着烷基链长度 (n) 的增加，构象从延伸/螺旋/延伸形式变为完全延伸形式。氧乙烯链的延伸结构稳定在 n ≥ 3。该实验发现表明，三嵌段化合物中氧乙烯嵌段的延伸结构由长度与氧乙烯嵌段相当或更长的末端烷基嵌段稳定. 这项研究的结果，

  DOI：

  10.1016/s0022-2860(97)00317-7
• 作为产物：
  描述：

  2-(2-丙氧乙氧基)乙醇 在 吡啶 、 氯化亚砜 作用下， 生成 1-[2-(2-chloro-ethoxy)-ethoxy]-propane
  参考文献：
  名称：

  Mamedov,S. et al., Journal of Organic Chemistry USSR (English Translation), 1966, vol. 2, p. 656 - 659

  摘要：

  DOI：

文献信息

• Isatoic anhydride derivatives and applications thereof
  申请人：The University of North Carolina at Charlotte

  公开号：US10179175B2

  公开（公告）日：2019-01-15

  Isatoic anhydride derivatives having an N-substituent which includes a quaternary ammonium group are useful for labeling and/or functionalizing a target material and/or for coupling materials together. The isatoic anhydride derivatives of the present disclosure can be advantageously water soluble, easily prepared and purified. Isatoic anhydride derivatives useful in the present disclosure preferably have at least one chemically reactive group or at least one binding group or at least one detectable label. Anthranilate derivatives made from the isatoic anhydrides derivatives or otherwise and kits including the isatoic anhydride derivatives are also disclosed.

  具有包括季铵基团的 N 取代基的异酸酐衍生物可用于标记和/或官能化目标材料和/或将材料耦合在一起。本公开的异酸酐衍生物可溶于水，易于制备和纯化。本公开中有用的异酸酐衍生物最好具有至少一个化学反应基团或至少一个结合基团或至少一个可检测标签。此外，还公开了由异酸酐衍生物或其他衍生物制成的蒽酸衍生物以及包括异酸酐衍生物的试剂盒。
• SOLUTION ABSORBANTE CONTENANT UN MÉLANGE DE 1,2-BIS-(2-DIMÉTHYLAMINOÉTHOXY)-ÉTHANE ET DE 2-[2-(2-DIMÉTHYLAMINOÉTHOXY)-ÉTHOXY]-ÉTHANOL, ET PROCÉDÉ D'ÉLIMINATION DE COMPOSÉS ACIDES D'UN EFFLUENT GAZEUX
  申请人：IFP Energies nouvelles

  公开号：EP3148674B1

  公开（公告）日：2018-07-11
• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION
  申请人：NADLER Jerry L.

  公开号：US20080300189A1

  公开（公告）日：2008-12-04

  Pharmaceutical compositions and methods for using are provided for restoring β-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a β-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.
• ENCAPSULATION SYSTEM
  申请人：Nadler Jerry L.

  公开号：US20090269313A1

  公开（公告）日：2009-10-29

  An encapsulation system for use in the treatment of diabetes (Types 1 or 2, and LADA) are provided. The system has (1) a delivery vehicle comprising a selectively permeable membrane that allows passage of glucose, insulin and other nutrients through the membrane, but prevents large molecules such as antibodies or inflammatory cells from passing through the membrane; (2) a population of islet cells or insulin producing cells encapsulated by said membrane; and (3) a biological response modifier that may be in contact with the membrane or encapsulated by the membrane. Generally, the biological response modifier is a compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula: wherein: X, Y and Z are independently selected from a member of the group consisting of C(R 3 ), N, N(R 3 ) and S; R 1 is selected from a member of the group consisting of hydrogen, methyl, C (5-9) alkyl, C (5-9) alkenyl, C (5-9) alkynyl, C (5-9) hydroxyalkyl, C (3-8) alkoxyl, C (5-9) alkoxyalkyl, the R 1 being optionally substituted; R 2 and R 3 are independently selected from a member of the group consisting of hydrogen, halo, oxo, C (1-20) alkyl, C (1-20) hydroxyalkyl, C (1-20) thioalkyl, C (1-20) alkylamino, C (1-20) alkylaminoalkyl, C (1-20) aminoalkyl, C (1-20) aminoalkoxyalkenyl, C (1-20) aminoalkoxyalkynyl, C (1-20) diaminoalkyl, C (1-20) triaminoalkyl, C (1-20) tetraaminoalkyl, C (5-15) aminotrialkoxyamino, C (1-20) alkylamido, C (1-20) alkylamidoalkyl, C (1-20) amidoalkyl, C (1-20) acetamidoalkyl, C (1-20) alkenyl, C (1-20) alkynyl, C (3-8) alkoxyl, C (1-11) alkoxyalkyl, and C (1-20) dialkoxyalkyl.
• COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE
  申请人：Nadler Mary Ann Latona

  公开号：US20110052625A1

  公开（公告）日：2011-03-03

  Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal.